Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20090989 | 1.00 | GRIN1 (0.51) | GRIN1GRIN2BRAB9ATSHRHSD17B10 | |
| SCHEMBL24136387 | 0.86 | GRIN1 (0.68) | GRIN1GRIN2BRAB9ATSHRHSD17B10 | |
| SCHEMBL21864454 | 0.83 | KMT2A (0.53) | GRIN2BKMT2AL3MBTL1 | |
| SCHEMBL20090957 | 0.80 | GRIN1 (0.79) | GRIN1GRIN2B | |
| SCHEMBL24136447 | 0.77 | GRIN2B (0.45) | GRIN1GRIN2BKMT2A | |
| SCHEMBL20090983 | 0.77 | GRIN2B (0.45) | GRIN1GRIN2BKMT2A | |
| SCHEMBL22701630 | 0.73 | GRIN2B (0.57) | GRIN1GRIN2B | |
| SCHEMBL20091020 | 0.73 | GRIN2B (0.57) | GRIN1GRIN2B | |
| SCHEMBL25108838 | 0.73 | BCHE (0.57) | RAB9ABCHEALOX5GAAL3MBTL1 | |
| SCHEMBL28572476 | 0.72 | BCHE (0.60) | RAB9ATSHRBCHEALOX5NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200369610-A1 | N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | CADENT THERAPEUTICS, INC. (US) | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369610-A1 | N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | GRIN2A, GRIN2C, GRIN3A | GRIN1 5/4885GRIN2B 4/4885RAB9A 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.